60 Degrees Pharmaceuticals, Inc. (SXTP) · Nov 6, 2026 · Share issuance

60 Degrees Pharmaceuticals warrant financing raises $526K but doubles dilution

$526K warrant exercise — 584,492 shares exercised at $0.90; 1,168,984 new warrants

60 Degrees Pharmaceuticals’ warrant financing brings in $526K gross, but the cash comes with a sharp repricing and 1.17M new warrants.

60 Degrees Pharmaceuticals is a cash-constrained specialty drug company commercializing Arakoda for malaria prevention while funding a babesiosis treatment program aimed at a future supplemental FDA approval. Its June 2026 filing showed $1.02 million of cash, $4.97 million of operating cash burn in six months, and substantial doubt about continuing as a going concern; the company’s pipeline remains dependent on repeated equity financing.

The immediate benefit is real but small: warrant holders agreed to exercise 584,492 existing warrants for $526,042.80 of gross cash, which the company plans to use for working capital and general corporate purposes. Against the company’s prior cash needs, this is a liquidity bridge—not funding that materially changes the operating story.

The financing terms are notably expensive: existing warrant exercise prices ranging from $7.60 to $27.60 are being cut to $0.90, while investors receive new warrants covering twice as many shares as the warrants they exercise. This secures cash now, but makes future dilution substantially heavier and signals that capital providers had strong negotiating leverage.

The event helps survival more than it advances the business: the company also pays H.C. Wainwright 8.5% of gross proceeds in cash, $10,000 of expenses, and warrants for up to 43,837 additional shares at $1.125. The new warrants cannot be exercised until stockholder approval, with the company required to keep seeking approval every 90 days if needed, so the full dilution is deferred but not removed.

TransactionExisting termsNew terms
Warrant shares exercised (Item 1.01)584,492—$0.90
Gross proceeds (Item 1.01)$526,042.80——
New warrant shares (Item 1.01)1,168,984—200% of exercised shares
Exercise price (Item 1.01)$0.90$7.60–$27.60$0.90
Placement-agent warrants (Item 1.01)43,837—$1.125

Bottom line: This buys 60 Degrees Pharmaceuticals limited operating time, but only by accepting a highly dilutive repricing that weakens the quality of the financing. It modestly supports near-term liquidity while reinforcing—not resolving—the company’s dependence on repeated capital raises.

What to watch next

Stockholder vote on new warrant issuance within 90 days

Original filing on SEC EDGAR

More 60 Degrees Pharmaceuticals, Inc. news

60 Degrees Pharmaceuticals warrant financing raises $526K but doubles dilution | SXTP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.